GSA Capital Partners LLP Has $249,000 Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

GSA Capital Partners LLP cut its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 80.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,505 shares of the company's stock after selling 87,931 shares during the period. GSA Capital Partners LLP's holdings in Pediatrix Medical Group were worth $249,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MD. The Manufacturers Life Insurance Company grew its stake in shares of Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company's stock worth $245,000 after purchasing an additional 1,088 shares during the period. ProShare Advisors LLC grew its position in shares of Pediatrix Medical Group by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company's stock worth $170,000 after buying an additional 1,167 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. SummerHaven Investment Management LLC raised its position in shares of Pediatrix Medical Group by 3.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company's stock valued at $422,000 after acquiring an additional 2,069 shares during the period. Finally, Bank of Montreal Can boosted its stake in Pediatrix Medical Group by 0.5% during the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company's stock worth $3,196,000 after acquiring an additional 2,083 shares during the last quarter. Institutional investors own 97.71% of the company's stock.

Insiders Place Their Bets

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares of the company's stock, valued at $343,783.80. This represents a 18.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have weighed in on MD. Truist Financial increased their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a report on Monday, November 4th. UBS Group raised their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a report on Monday, November 4th. Finally, Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 19th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, Pediatrix Medical Group has an average rating of "Hold" and an average target price of $16.10.

Pediatrix Medical Group Stock Up 1.4 %

Shares of MD stock traded up $0.21 on Friday, hitting $14.96. 933,682 shares of the stock were exchanged, compared to its average volume of 815,756. The firm has a market capitalization of $1.28 billion, a P/E ratio of -4.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.55. The business has a 50-day moving average of $12.93 and a 200 day moving average of $10.05. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter in the previous year, the firm earned $0.29 EPS. The business's quarterly revenue was up .9% on a year-over-year basis. Equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.